0.10 | 0.58%
AUXILIUM PHARMA INC's gross profit margin for the first quarter of its fiscal year 2013 is essentially unchanged when compared to the same period a year ago. Sales and net income have dropped, although the growth in revenues underperformed the average competitor within the industry, the net income growth did not. AUXILIUM PHARMA INC is extremely liquid. Currently, the Quick Ratio is 5.55 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has increased from the same period last year.
At the same time, stockholders' equity ("net worth") has greatly increased by 161.83% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
| Income Statement | Q1 FY13 | Q1 FY12 |
|---|---|---|
| Net Sales ($mil) | 66.17 | 74.43 |
| EBITDA ($mil) | -2.24 | 1.19 |
| EBIT ($mil) | -5.09 | -1.12 |
| Net Income ($mil) | -8.16 | -1.75 |
| Balance Sheet | Q1 FY13 | Q1 FY12 |
|---|---|---|
| Cash & Equiv. ($mil) | 467.81 | 163.08 |
| Total Assets ($mil) | 642.61 | 311.69 |
| Total Debt ($mil) | 285.39 | 0.0 |
| Equity ($mil) | 231.96 | 88.59 |
| Profitability | Q1 FY13 | Q1 FY12 |
|---|---|---|
| Gross Profit Margin | 81.5 | 80.79 |
| EBITDA Margin | -3.38 | 1.6 |
| Operating Margin | -7.68 | -1.5 |
| Sales Turnover | 0.6 | 0.9 |
| Return on Assets | 12.37 | -7.32 |
| Return on Equity | 34.28 | -25.75 |
| Debt | Q1 FY13 | Q1 FY12 |
|---|---|---|
| Current Ratio | 5.85 | 2.94 |
| Debt/Capital | 0.55 | 0.0 |
| Interest Expense | 3.0 | 0.0 |
| Interest Coverage | -1.69 | 0.0 |
| Share Data | Q1 FY13 | Q1 FY12 |
|---|---|---|
| Shares outstanding (mil) | 49.31 | 48.32 |
| Div / share | 0.0 | 0.0 |
| EPS | -0.17 | -0.04 |
| Book value / share | 4.7 | 1.83 |
| Institutional Own % | n/a | n/a |
| Avg Daily Volume | 813642.0 | 873484.0 |
HOLD. The current P/E ratio indicates a significant discount compared to an average of 23.04 for the Pharmaceuticals industry and a discount compared to the S&P 500 average of 18.91. Conducting a second comparison, its price-to-book ratio of 3.61 indicates a premium versus the S&P 500 average of 2.42 and a significant discount versus the industry average of 7.00. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. Upon assessment of these and other key valuation criteria, AUXILIUM PHARMA INC proves to trade at a discount to investment alternatives within the industry.
| Price/Earnings |
|
Price/Cash Flow |
| |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AUXL 10.53 | Peers 23.04 | AUXL NM | Peers 17.33 | |||||||||||||||||||||
|
Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations. AUXL is trading at a significant discount to its peers. |
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures. AUXL's P/CF is negative making the measure meaningless. |
|||||||||||||||||||||||
| Price/Projected Earnings |
|
Price to Earnings/Growth |
|
|||||||||||||||||||||
| AUXL 25.70 | Peers 15.35 | AUXL NM | Peers 0.71 | |||||||||||||||||||||
|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings. AUXL's ratio is negative making this valuation measure meaningless. |
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples. AUXL's negative PEG ratio makes this valuation measure meaningless. |
|||||||||||||||||||||||
| Price/Book |
|
Earnings Growth |
|
|||||||||||||||||||||
| AUXL 3.61 | Peers 7.00 | AUXL 435.41 | Peers -9.53 | |||||||||||||||||||||
|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet. AUXL is trading at a significant discount to its peers. |
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios. AUXL is expected to have an earnings growth rate that significantly exceeds its peers. |
|||||||||||||||||||||||
| Price/Sales |
|
Sales Growth |
|
|||||||||||||||||||||
| AUXL 2.16 | Peers 5.75 | AUXL 38.33 | Peers 7.49 | |||||||||||||||||||||
|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales. AUXL is trading at a significant discount to its industry on this measurement. |
Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share. AUXL has a sales growth rate that significantly exceeds its peers. |
|||||||||||||||||||||||
